Astaxanthin

Clinical Summary

Astaxanthin is a keto-carotenoid produced by the microalga Haematococcus pluvialis. Humans cannot synthesize it; dietary sources include salmon, shrimp, and krill. It is one of the most potent lipid-soluble antioxidants studied, with a unique molecular structure that spans biological membranes end-to-end — hydroxyl groups anchor at membrane surfaces while the polyene chain embeds within the lipid bilayer.

The compound has moderate-strong clinical evidence across several domains: oxidative stress biomarker reduction (multiple meta-analyses), exercise performance and recovery (consistent RCT data), and skin photoprotection (multiple RCTs). Evidence for metabolic health, cognitive support in elderly, and cardiovascular LDL oxidation resistance is moderate but less consistent. Female reproductive health (PCOS, ART outcomes) is now the most active clinical research area with 7+ RCTs from 2024-2026, though still dominated by a single lab group. Emerging preclinical domains include bone health (osteonecrosis, fracture healing, osteoporosis — 4 animal studies since 2024), kidney protection (diabetic nephropathy, CKD, nephrotoxicity — 4+ studies), mood/anxiety (first dedicated animal study 2026), and oncology supportive care (first human chemoprotection RCT 2024). Autoimmune and neurodegenerative applications remain largely preclinical.

Key mechanisms: Nrf2 pathway activation (upregulating SOD, catalase, GPx, HO-1), NF-κB inhibition (reducing IL-6, TNF-α, COX-2), mitochondrial membrane stabilization, and direct ROS scavenging. Unlike beta-carotene, astaxanthin does NOT become pro-oxidant at high concentrations. It crosses the blood-brain barrier and blood-retinal barrier.

Safety profile is excellent — no serious adverse events reported up to 40 mg/day for 12 weeks. FAERS database shows zero reports where astaxanthin was the suspect drug (all 403 reports are concomitant medication noise). One meta-analysis found astaxanthin may increase ALT (but not AST/GGT/ALP) — clinical significance unclear; monitor in hepatically impaired patients. The only clinically notable drug interaction is a single case report of warfarin potentiation (PMID: 31073352), now mechanistically confirmed by a 2026 study showing dual platelet activation + coagulation cascade inhibition (PMID: 41702374).

Astaxanthin is obtained at low levels (~1–2 mg) via Krill Oil in the current stack but no dedicated supplement is taken.

Indications & Evidence

Reading this table: Stars = evidence volume and quality. Type = causal relationship (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7–9=strong causal | 5–6=moderate | 3–4=weak | 1–2=speculative Safety flags: -- No FAERS signals (astaxanthin has zero suspect-drug reports) | MON Monitor | WARN FAERS signal | AVOID Contraindicated

Star rating legend: 5/5 = multiple large RCTs + meta-analyses | 4/5 = several human RCTs | 3/5 = some human pilot or strong animal + mechanistic | 2/5 = animal only or very limited human | 1/5 = none, theoretical, or debunked

Prescribing

Dosing Table

Formulation Table

Critical: Must take with ≥10 g dietary fat. Empty-stomach bioavailability <20%. No cycling required — continuous use recommended. Benefits are cumulative via tissue saturation (4–12 wk).

Safety

Interactions Table

Contraindications

• Absolute: Known allergy to astaxanthin or Haematococcus algae (rare)
• Relative: Active bleeding disorders; scheduled surgery (discontinue 2 wk prior — theoretical); severe hepatic impairment (accumulates in liver, though hepatoprotective); hypotension (<90/60 mmHg)
• Pregnancy/lactation: Insufficient data — avoid supplementation (dietary sources acceptable)

Adverse Effects (ranked by frequency)

• Common (>1%): Skin discoloration (5–15% at >12 mg/d — harmless orange-pink, reversible); GI upset (3–8%, dose-dependent, improves with food); stool color change (5–10%, harmless)
• Uncommon (0.1–1%): Loose stools at >16 mg/d (1–2%); headache (<1%)
• Rare (<0.1%): Allergic reactions (urticaria); symptomatic hypotension; ALT elevation (meta-analysis found AST ↑ ALT but not AST/GGT/ALP — clinical significance unclear, monitor in hepatic impairment)
• No serious adverse events reported in clinical trials up to 40 mg/day × 12 wk

FAERS Signal Table (from BioMCP)

Reading FAERS data: Astaxanthin has zero suspect-drug reports in the FAERS database. All 403 reports list astaxanthin as a concomitant medication — the suspect drugs are chemotherapy agents (lenalidomide), biologics (infliximab, etanercept), and other pharmaceuticals. This is the classic supplement FAERS noise pattern: patients on serious medications also happen to take astaxanthin. None of these reactions are attributable to astaxanthin.

Monitoring Table

Synergies & Stacking

Antagonistic interactions: None identified. High-dose vitamin A / beta-carotene may theoretically compete for carotenoid absorption, but not clinically significant at supplemental doses. Excessive fiber (>50 g/d) may reduce fat-soluble absorption generally.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No known pharmacogenomic modifiers specifically validated for astaxanthin in clinical studies. The above are mechanistic extrapolations from the carotenoid/antioxidant class.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Positive across ~3,000+ reports (Reddit r/Supplements, r/Nootropics, r/longevity, Longecity, Examine.com community). Astaxanthin is generally well-regarded as a "boring but reliable" antioxidant. Hype level has increased since 2024 — the ITP mouse lifespan study generated a longevity community surge, with AgelessRx and similar longevity companies repositioning astaxanthin as a "longevity agent." This is premature marketing of AHE-level evidence (the full ITP 2026 follow-up was NEGATIVE for lifespan extension). Supplement sales for "longevity support" reportedly spiked ~45% in 2024.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No. Astaxanthin is not associated with MLM distribution.
• Influencer concentration: Broad-based. Multiple science communicators mention it (Examine, Huberman, Rhonda Patrick). Now expanding into longevity-specific channels (AgelessRx, Peter Attia adjacent). Not driven by 1–2 people.
• Astroturfing signals: Low overall. Exception: Belano brand (see below) shows suspicious positive review clusters.
• Commercial bias: AstaReal (Fuji Chemical Industries) funds most clinical research. Positive study ecosystem may reflect funder bias, though independent replication exists. Brand recommendations in communities track toward AstaReal-sourced products.
• BRAND RED FLAG — Belano: Aggressively marketed to biohackers in 2025-2026 with severe consumer complaints: invalid tracking numbers, non-delivery, ghost customer service. Claims "fasted absorption" without food — directly contradicts known bioavailability requirements. Community consensus: avoid.
• Product quality crisis: Broadening beyond the NOW Foods 2023 finding. One audit found 4 of 9 tested brands contained <50% claimed content. This likely explains many "didn't work" reports. Third-party-tested brands are critical.
• Longevity marketing overreach: AgelessRx and similar companies positioning astaxanthin as "proven longevity compound" based on earlier ITP mouse data — but the full ITP 2026 study (PMID: 41843349) showed astaxanthin does NOT extend lifespan. AHE evidence being marketed as DC-level.

Folk vs Clinical Reality Check

Community experience largely aligns with clinical data: sunburn protection, exercise recovery, and skin improvements are the most commonly reported benefits, matching the strongest evidence tiers. The ~30% "no effect" reports are consistent with the modest effect sizes (d=0.3–0.6) seen in RCTs — not everyone notices a supplement with small-to-moderate effects. Community dosing has shifted upward to center on 12 mg/d (from the previous 8–12 range), which matches the higher end of clinical evidence. The main divergence is the emerging "longevity agent" framing — community perception surged after early ITP data, but the definitive ITP 2026 study was NEGATIVE. Cognitive benefit reports are growing (brain fog reduction) but evidence remains marginal (Liu 2024 MA: "marginally significant"). Joint pain reduction is a newer community signal aligned with the RA trial (PMID: 40569081). Hair growth claims remain unsupported — a Japanese RCT found reduced hair dryness but not growth. Mood/sleep reports remain sparse but align with the first dedicated animal study (PMID: 41929257). The submaximal heart rate reduction (~10%) reported by endurance athletes is a specific, measurable claim worth investigating clinically. Product underdosing (~25-44% of brands failing potency) likely explains many "didn't work" reports — this is a supply chain problem, not a compound problem.

Deep Dive: Mechanisms & Research

Core Mechanisms (with clinical translation status)

Nrf2 Pathway Activation (clinically translated ✓): Upregulates endogenous antioxidant enzymes — SOD, catalase, GPx, HO-1, NQO1. This is the primary mechanism behind the consistent oxidative stress biomarker improvements seen across multiple meta-analyses. Clinical translation is confirmed by MDA reduction, SOD increase, and isoprostane reduction in human RCTs.

NF-κB Inhibition (partially translated): Suppresses IKK → IκB → NF-κB cascade, reducing IL-1β, IL-6, TNF-α, COX-2, iNOS. The Ma 2022 meta-analysis confirmed IL-6 reduction in T2DM patients but NOT significant CRP or TNF-α reduction overall. Translation is incomplete — anti-inflammatory biomarker changes are inconsistent across populations.

Mitochondrial Membrane Stabilization (preclinical): Preferentially accumulates in mitochondrial membranes. Stabilizes ETC, reduces electron leakage, preserves membrane potential, protects cardiolipin. Supported in cell culture and animal models. Clinical translation: the fat oxidation enhancement during exercise (Liu 2024 MA: SMD 2.56) may reflect this mechanism, but direct human mitochondrial data is limited.

Membrane Spanning Architecture (unique property): Astaxanthin spans the entire phospholipid bilayer — terminal hydroxyl groups at each membrane surface, polyene chain embedded centrally. This is structurally unique among carotenoids and explains its non-pro-oxidant behavior: unlike beta-carotene, it doesn't become a radical propagator at high oxygen tensions. Confirmed spectroscopically in membrane models.

BBB and Blood-Retinal Barrier Penetration (partially translated): Astaxanthin crosses both barriers, accumulating in brain and retinal tissue. Cognitive RCTs show modest benefits (d=0.3–0.5) in elderly. AD trial (NCT05015374, N=46) completed; results pending. Eye fatigue trials show improvement. Retinal Muller cell protection via SIRT1/AMPK/FOXO1 pathway (PMID: 41581827). Full neuroprotective translation awaits larger trials.

Ferroptosis Inhibition (preclinical, rapidly expanding): Emerging as a unifying mechanism across multiple organ systems. Astaxanthin inhibits ferroptosis via: Nrf2-ferroptosis axis in UC (PMID: 41338419), Akt1-FoxO3a in hemorrhagic stroke (PMID: 41241442), JAK2/STAT3 in bone necrosis (PMID: 39903514), and macrophage polarization in MI (PMID: 39495463). Clinical translation: none yet, but the multi-organ ferroptosis data is mechanistically compelling.

cGAS-STING Pathway (preclinical): New target for hepatoprotection — astaxanthin attenuates alcoholic liver injury via pyroptosis-mitochondrial homeostasis crosstalk through cGAS-STING (PMID: 41649288). Adds a distinct mechanism beyond Nrf2/NF-κB for liver protection.

Gut-Organ Axes (preclinical): Gut-brain axis post-stroke (PMID: 41559375), gut-kidney axis for hyperuricemia (PMID: 41067355), gut-prostate axis via Akkermansia colonization (PMID: 38056144). Suggests astaxanthin's effects may be partially microbiome-mediated, though the UC study (PMID: 41338419) found ferroptosis protection was independent of microbiota.

Pharmacokinetics Summary

• Absorption: 40–60% (natural di-ester with fat); SR-B1, NPC1L1, and CD36 transporter-mediated (CD36 shows stereoisomeric selectivity — PMID: 41631482)
• Peak plasma: 6–8 hours; Z-isomers 1.2–1.7× higher bioavailability (PMID: 33689342)
• Half-life: 16–52 hours
• Distribution: LDL (60–70%), HDL (20–30%), VLDL (10–15%); accumulates in brain, retina, skin, liver, adipose
• Metabolism: Minimal CYP450 involvement (<15% hepatic extraction); primarily lipid transport
• No cycling required: No receptor downregulation, no tolerance, benefits increase with tissue saturation

Clinical Trials (from BioMCP / ClinicalTrials.gov)

| NCT07509970 | Astaxanthin on Soccer Performance Under Fatigue | — | Completed | Exercise fatigue | 30 | 2026 | | NCT06589128 | Astaxanthin for Digital Eye Strain in Children | — | Enrolling | Pediatric DES | 70 | 2024–2025 | | NCT04689984 | Astaxanthin Add-on for Painful Diabetic Neuropathy | 2/3 | Unknown | Diabetic neuropathy | 60 | 2020–2021 | | NCT06429059 | ROAR-DIGAP Personalized Therapy for ALS (AST arm) | 2 | Completed | ALS | 50 | 2024–2025 | | NCT07475546 | Combination Gerotherapeutics (rapamycin+AST+...) | 3 | Active | Healthspan/longevity | 30 | 2025–2026 | | NCT07406906 | Dietary Supplement (incl AST) for Myopia | — | Not yet recruiting | Myopia | 156 | 2026 | | NCT06511960 | Astaxanthin 12mg vs 36mg on Exercise Muscle Damage | — | Completed | Exercise dose-response | 24 | 2023–2024 | | NCT05138549 | Astaxanthin for Knee OA Inflammation | 2/3 | Terminated | Knee OA | 16 | 2022–2023 |

69 total registered trials on ClinicalTrials.gov. ~30 completed, 4–5 actively recruiting (2026). Key upcoming: brain aging dose-response trial (N=120, Capital Medical University) will be the largest cognitive trial to date. Notable: longevity combination trial with rapamycin (NCT07475546) and ALS personalized therapy (NCT06429059) represent novel therapeutic territory.

Regulatory Status (from BioMCP)

• FDA: GRAS (Generally Recognized as Safe); not an approved drug; sold as dietary supplement
• EMA: Novel Food approved (EU)
• Health Canada: Licensed Natural Health Product
• WADA: Not prohibited
• Regulatory context: Astaxanthin from H. pluvialis has GRAS status. Synthetic astaxanthin is used primarily in aquaculture feed. No pharmaceutical company has pursued drug approval because the compound is non-patentable (natural) and the indications don't justify the ROI of full drug development. This is a commercial decision, not a safety signal.

Ataraxia Verdict (as of 2026-04-14)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale below.

Hype Check (Mode 1: Fallacy Radar)

• "550× stronger than vitamin E" / "6,000× stronger than vitamin C": These are in vitro singlet oxygen quenching assays under specific laboratory conditions. They do NOT mean astaxanthin is 550× more effective as a supplement. Different assays, different concentrations, different biological contexts. This is the single most common astaxanthin marketing exaggeration.
• Hasty generalization (animal → human): The file's original ratings of 3/5–4/5 for autoimmune hepatitis, MS, IBD, and neuroprotection were based on animal data. Per causal taxonomy, these cap at 2/5. Downgraded.
• Cherry-picking positive studies: Wu 2019 systematic review actually concluded "the antioxidant effect of astaxanthin on humans is unclear," and the newest 2026 exercise MA found only AOPP reduction significant while MDA/SOD/CK/IL-6 were NOT. The file's original 5/5 for exercise was generous.
• Appeal to authority: AstaReal is a commercial brand, not a scientific authority. It appears in the file as "clinical gold standard" — accurate that most RCTs use it, but this reflects industry funding, not independent validation.
• Argument from mechanism: Many claimed benefits rely on known mechanisms (Nrf2, NF-κB) projected onto clinical outcomes without direct testing. The surrogate endpoint trap applies: antioxidant biomarker improvement has historically failed to predict clinical benefit (vitamin E, beta-carotene, SELECT trial).

Evidence Gaps

1. No long-term (>1 year) human RCT safety data — most trials are 8–16 weeks
2. Pediatric data now emerging — first pediatric DES RCT (PMID: 40014233) + enrolling trial (NCT06589128), but still very limited
3. No pregnancy RCTs — animal safety data only; human data is a critical gap
4. Hair growth unstudied — one Japanese RCT found reduced hair dryness, but no data on growth, color, or graying (Nutrafol trials contain astaxanthin but as minor component)
5. Sleep effects unstudied — no RCTs examining sleep architecture or quality
6. Mood / depression: first dedicated animal study published 2026 (PMID: 41929257); still no human RCTs
7. Pharmacogenomics: zero studies on genetic modifiers of astaxanthin response — confirmed gap after exhaustive search
8. Sex-specific dosing: not studied — male vs female dose-response unknown; muscle progenitor study (PMID: 41519810) suggests sexual dimorphism exists
9. Bone effects: 4 animal studies since 2024 (osteonecrosis, fracture, osteoporosis) but OA trial (NCT05138549) terminated at N=16; no human bone data
10. Kidney protection: 4+ animal studies since 2024 (nephrotoxicity, CKD, diabetic nephropathy, gut-kidney axis); no human data
11. Microbiome effects: animal data expanding (Akkermansia colonization, gut-brain axis post-stroke); no human studies
12. Hard clinical endpoints: NO astaxanthin trial has measured mortality, cardiovascular events, cancer incidence, or dementia diagnosis as a primary endpoint — and the ITP 2026 definitive negative for lifespan reinforces this gap
13. ALT elevation: meta-analysis found astaxanthin may increase ALT; clinical significance and mechanism unknown

Bias Flags (Mode 4: First Principles)

• Industry funding dominance: AstaReal (Fuji Chemical Industries) sponsors most astaxanthin research. Most RCTs use AstaReal product. This creates a publication bias risk — negative results may be suppressed.
• Geographic concentration: Large proportion of studies from Japan and Iran. Japanese studies are generally high-quality; Iranian fertility studies are from a single lab (Amidi, Tehran University).
• Surrogate endpoint trap is the central issue: All "proven" benefits are biomarker improvements (MDA, SOD, isoprostanes, CK, LDH, CRP). No trial has demonstrated that astaxanthin prevents disease, extends lifespan, or reduces mortality. The vitamin E and beta-carotene precedents demand caution.
• Effect size inflation: The original file cited TTE +18% (Tsao 2025) as headline evidence — but N=10, single trial, 4-day supplementation, from one lab. This is a pilot, not definitive evidence.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: The "550× stronger than vitamin E" claim is the primary marketing manipulation. It appears on virtually every astaxanthin product page, supplement review site, and marketing brief. It's technically derived from a single in vitro assay (Miki 1991, singlet oxygen quenching) but is presented as if it means clinical superiority. Second-most common: "the king of carotenoids" — marketing language, not science.
• Influencer economics: Broad-based ecosystem. Examine.com provides balanced, evidence-weighted coverage. Andrew Huberman, Rhonda Patrick, and multiple health YouTubers mention astaxanthin but not as a primary product push. No single influencer drives the market.
• Longevity marketing overreach (NEW): AgelessRx and longevity supplement companies began marketing astaxanthin as a "proven longevity compound" after early ITP mouse data. The definitive ITP 2026 study (PMID: 41843349) showed astaxanthin does NOT extend lifespan — but this correction has not reached marketing materials. This is AHE-level evidence being sold as DC-level.
• Counter-narrative manipulation: Minimal. No competing pharmaceutical product creates incentive for anti-astaxanthin FUD. The FDA has not raised safety concerns beyond standard supplement labeling requirements.
• Cui bono summary: Algae cultivation companies (Fuji Chemical/AstaReal, Cyanotech/BioAstin) and supplement brands profit from astaxanthin sales. No specific entity profits from you NOT taking it. The financial incentive is one-directional — toward promoting the compound.
• Red team highlight: The most concerning angle is the surrogate endpoint trap, now REINFORCED by the ITP 2026 negative lifespan result. Astaxanthin's excellent antioxidant biomarker effects (MDA ↓, SOD ↑) did not translate to lifespan extension in genetically heterogeneous mice. This is the beta-carotene/vitamin E pattern playing out in real-time: biomarker wins that don't become clinical wins. The non-pro-oxidant property is genuinely novel, but the ITP result demands humility. Additionally, the ALT elevation finding (meta-analysis) adds a new safety nuance to a previously "clean" profile — minor, but worth monitoring.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 6/10 — moderate evidence for membrane-level antioxidant protection, exercise recovery, and skin/eye health; incremental optimization compound with narrow breadth of strong clinical indications.
• Opportunity cost: ~$30–50/month for 12 mg/d natural extract. One more capsule in an already substantial stack. Low financial cost; marginal complexity cost.
• Hell Yes or No (Sivers test): Not a Hell Yes. Evidence is moderate-strong but effects are modest. Safety is excellent. It's a solid "probably fine" supplement, not a game-changer.
• Regret minimization: Low regret either way. The safety profile means downside risk is near-zero. The upside is incremental.
• Verdict: CONDITIONAL — add if: (a) heavy exercise / outdoor UV exposure is a priority, (b) you want to optimize the krill oil synergy already in the stack, or (c) oxidative stress markers are elevated on bloodwork. Otherwise, current stack is adequate.
• Conditions: Upgrade to ADD if future bloodwork shows elevated MDA/isoprostanes, or if the brain aging dose-response trial (NCT07379437, 2026–2027) shows strong cognitive results.

Bottom Line

Astaxanthin is a well-studied, exceptionally safe carotenoid with genuine moderate-level evidence for oxidative stress reduction, exercise recovery, and skin photoprotection. The marketing significantly oversells it ("550× stronger!"), and the file's original ratings inflated several animal-only claims. The central question — "do biomarker improvements translate to clinical outcomes?" — remains unanswered, as it does for most antioxidant supplements. The compound does NOT become pro-oxidant (unlike beta-carotene), which is a genuine structural advantage. For biohackers already taking omega-3 and CoQ10, astaxanthin provides complementary but overlapping coverage. Verdict: CONDITIONAL — good compound, not essential in a well-rounded stack, worth adding for specific goals (exercise, skin, UV protection) or if biomarkers indicate need.

Practical Notes

First choice formulation: Natural Haematococcus pluvialis extract (AstaReal, BioAstin, Valensa). Most clinical evidence; natural 3S,3'S stereoisomer.

Storage: Light-sensitive — store in opaque container, dark location. Room temp (15–25°C). Shelf life 2–3 years unopened. Discard if capsules fade to pale pink (oxidized).

Fat requirement is non-negotiable: Without ≥10 g dietary fat, absorption drops below 20%. Take with meals containing olive oil, avocado, nuts, fatty fish, or eggs. For IF/time-restricted protocols: only take during eating window.

Split dosing for high doses: If ≥12 mg/d, split into 2 doses to reduce GI upset and improve absorption.

Patience required: Unlike acute antioxidants (vitamin C), astaxanthin requires 4–12 weeks of tissue saturation for benefits. Don't expect immediate effects.

Skin discoloration is not toxicity: Orange-pink tint at >12 mg/d is tissue accumulation — reversible upon discontinuation. Some biohackers consider it a visible marker of tissue saturation. Harmless.

Quality markers: Look for AstaReal certification, USP Verified, NSF Certified for Sport (athletes), or ConsumerLab approval. Avoid: proprietary blends, undisclosed stereoisomer content, suspiciously low prices (<$20/month for 12 mg/d natural). Potency warning (CRITICAL): Product quality crisis is broadening — one 2025 audit found 4 of 9 tested brands contained <50% of claimed content (building on 2023 NOW Foods findings of ~25% failure rate). This likely explains many "didn't work" community reports. Third-party-tested brands are essential. Avoid Belano brand specifically — severe consumer complaints (non-delivery, ghost customer service, claims "fasted absorption" which contradicts known bioavailability).

What We Don't Know

• Whether oxidative stress biomarker improvements translate to disease prevention or lifespan extension — the ITP (Interventions Testing Program) found astaxanthin did NOT extend lifespan in UM-HET3 mice (PMID: 41843349, GeroScience 2026). This is a rigorous multi-site negative result that tempers longevity claims.
• Long-term safety beyond 12 weeks at high doses (>12 mg/d for >1 year)
• Effects in pregnant/lactating women (pediatric data now emerging: PMID 40014233, NCT06589128)
• Optimal dose by specific condition — the 12mg vs 36mg exercise trial (NCT06511960) will help but results not yet published
• Pharmacogenomic modifiers — exhaustive search confirms zero studies; who responds well vs poorly remains unknown
• Sex-specific dosing differences (muscle progenitor sexual dimorphism PMID: 41519810 suggests differences exist)
• Effects on hair growth (dryness improved in one RCT; growth/graying unstudied), sleep architecture, bone density in humans
• Microbiome interactions
• Whether the Alzheimer's trial (NCT05015374, completed 2024) shows positive results
• Whether the brain aging dose-response trial (NCT07379437, N=120) will clarify cognitive benefit
• Head-to-head comparisons with other carotenoids (lutein, lycopene) for specific endpoints
• Whether the pro-oxidant-free property confers long-term safety advantages over other antioxidants
• Clinical significance of ALT elevation found in meta-analysis
• Whether CD36-mediated stereoisomeric selectivity (PMID: 41631482) should change formulation recommendations
• Results of ALS personalized therapy trial (NCT06429059) and longevity combination trial with rapamycin (NCT07475546)
• Whether bone, kidney, mood, and oncology supportive effects translate from animal/early human to clinical practice

References

Meta-Analyses & Systematic Reviews

1. Ma B et al. (2022) Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers. Nutr Res 99:40-50. PMID: 35091276 — 12 RCTs (N=380): MDA ↓ significant; IL-6 ↓ in T2DM; CRP and TNF-α NS.
2. Wu D et al. (2019) Effects of Astaxanthin Supplementation on Oxidative Stress. Int J Vitam Nutr Res 90(1-2):179-194. PMID: 30982442 — 9 RCTs: high dose (≥20 mg) significant; conclusion: "antioxidant effect unclear."
3. Ursoniu S et al. (2015) Lipid profile and glucose changes after astaxanthin supplementation. Arch Med Sci 11(2):253-66. PMID: 25995739 — 7 RCTs (N=280): no significant lipid or glucose changes; slight glucose-lowering trend.
4. Laurindo LF et al. (2025) Moderate to High Dosage Astaxanthin on Lipid Profile. Pharmaceuticals 18(8). PMID: 40872489 — 8 studies: HDL ↑ and TG ↓ significant at 6–20 mg/d; LDL and TC NS.
5. You T et al. (2026) Astaxanthin on exercise-induced oxidative stress. 3 Biotech 16(3):98. PMID: 41710469 — 7 RCTs (N=188): AOPP ↓ significant; MDA, SOD, CK, IL-6 NS. "Broader benefits remain unconfirmed."
6. Liu C et al. (2024) Astaxanthin on Fatigue, Motor Function and Cognition. Biol Res Nurs 26(3):469-480. PMID: 38243785 — 11 RCTs (N=346): fat oxidation ↑ significant (SMD 2.56); aerobic performance ↑; cognition marginally significant.
7. Laurindo LF et al. (2025) Astaxanthin for Body Weight Regulation. Pharmaceuticals 18(10). PMID: 41155597 — 9 trials: no significant BMI or body weight reduction.
8. Dehpahni MF et al. (2026) Astaxanthin in Male Infertility. Sci Rep 16(1). PMID: 41714744 — 10 studies: no significant human semen improvements; animal data positive.
9. Rodrigues VD et al. (2024) Astaxanthin in PCOS. Naunyn Schmiedebergs Arch Pharmacol 398(2):1155-1169. PMID: 39269488 — MA of RCTs: oxidative stress and reproductive improvements.
10. Maleki-Hajiagha A et al. (2024) Astaxanthin on Female Fertility. J Ovarian Res 17(1):163. PMID: 39127677 — Oocyte maturation ↑8.4%, TAC ↑; other ART outcomes NS.
11. Heydari SS et al. (2025) Carotenoid supplementation on liver enzymes. BMC Complement Med Ther 26(1):25. PMID: 41437050 — 15 studies (N=757): ALT/AST ↓ significant in non-healthy subgroups.
12. Yang Q et al. (2025) Dietary supplements for skin photoaging. Front Med PMID: 40761858 — MA of RCTs on skin photoaging supplements.

Landmark RCTs

13. Tsao JP et al. (2025) Astaxanthin on cycling performance. BMC Sports Sci Med Rehabil 17(1):180. PMID: 40615903 — N=10, 28 mg/d × 4 days: TTE +18% (85.4 vs 72.1 min, p<0.001).
14. Grigorian A et al. (2025) Astaxanthin in rheumatoid arthritis. Food Funct 16(14):5850-5858. PMID: 40569081 — N=60, 20 mg/d × 8 wk: DAS-28 ↓, HAQ ↓, ESR ↓.
15. Sekikawa T et al. (2020) Cognitive function with astaxanthin + tocotrienols. J Clin Biochem Nutr 67(3):307-316. PMID: 33293773 — N=36 analyzed, 12 mg AST + tocotrienols × 12 wk: composite memory ↑.
16. Katagiri M et al. (2012) Astaxanthin-rich H. pluvialis on cognitive function. J Clin Biochem Nutr 51(2):102-7. PMID: 22962526 — N=96, 6–12 mg × 12 wk: cognitive improvements.
17. Jabarpour M et al. (2024) Astaxanthin in PCOS. Phytother Res 38(1):321-330. PMID: 37874168 — N=58, 12 mg/d × 8 wk: HOMA-IR ↓, lipids ↓, MDA ↓.
18. Rostami S et al. (2023) Astaxanthin in endometriosis + ART. Front Endocrinol 14:1144323. PMID: 37020589 — N=50, AST improved ART outcomes.
19. Shafie A et al. (2024) Astaxanthin in poor ovarian responders. J Ovarian Res 17(1):212. PMID: 39482765 — AST improved ART outcomes.
20. Barker GA et al. (2023) Astaxanthin reduces DOMS in resistance-trained men. Muscles 2(2):228-237. PMID: 40757570.
21. Nieman DC et al. (2023) Astaxanthin counters exercise-induced protein decreases. Front Nutr 10:1143385. PMID: 37025615 — 82 plasma proteins preserved during 24h recovery.
22. Hayashi M et al. (2018) Astaxanthin from P. carotinifaciens on cognitive function. J Clin Biochem Nutr 62(2):195-205. PMID: 29610561.

Safety, Bioavailability & Mechanism Studies

23. Santiyanon N, Yeephu S. (2019) Warfarin-astaxanthin interaction case report. J Cardiol Cases 19(5):173-175. PMID: 31073352 — Probable interaction; INR ↑ and bleeding in 69-yo woman.
24. Honda M et al. (2021) Z-isomers have 1.2–1.7× higher bioavailability. J Agric Food Chem 69(11):3489-3495. PMID: 33689342.
25. Ambati RR et al. (2014) Comprehensive review: sources, stability, biological activities. Mar Drugs 12(1):128-52. PMID: 24402174.
26. Davinelli S et al. (2018) Astaxanthin in Skin Health, Repair, and Disease. Nutrients 10(4):522. PMID: 29690549.

Disease-Specific & Mechanism Studies

27. He Y et al. (2024) Astaxanthin alleviates autoimmune hepatitis via CD8+ T cells. Adv Sci 11(30):e2403148. PMID: 38874408 — Mouse model; mass cytometry + scRNA-seq.
28. Sakai S et al. (2019) Astaxanthin prevents DSS-induced colitis. J Clin Biochem Nutr 64(1):66-72. PMID: 30705514 — Mouse model.
29. Bidaran S et al. (2018) Astaxanthin prevents EAE (MS model). Bratisl Lek Listy 119(3):160-166. PMID: 29536745 — Mouse model.
30. Visioli F, Artaria C. (2017) Astaxanthin in cardiovascular health. Food Funct 8(1):39-63. PMID: 27924978.
31. Fassett RG, Coombes JS. (2011) Astaxanthin in cardiovascular disease. Mar Drugs 9(3):447-65. PMID: 21556169.
32. Gowd V et al. (2021) Antidiabetic potential of astaxanthin. Mol Nutr Food Res 65(24):e2100252. PMID: 34636497.
33. Landon R et al. (2020) Impact on diabetes pathogenesis. Mar Drugs 18(7):357. PMID: 32660119.
34. Feng W et al. (2020) Astaxanthin in gestational diabetes (mouse). Dose Response 18(2). PMID: 32501299.
35. Fassett RG, Coombes JS. (2012) Astaxanthin in cardiovascular health. Molecules 17(2):2030-48. PMID: 22349894.
36. Fassett RG, Coombes JS. (2009) Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol 5(4):333-42. PMID: 19656058.
37. Hajisoltani R et al. (2025) Astaxanthin for spinal cord injury recovery (preclinical MA). Neurol Res Int. PMID: 40786962.
38. Wan S et al. (2024) Antioxidant lipid supplement on cardiovascular risk factors (MA). Nutrients. PMID: 39064656.
39. Babaei Hoolari B et al. (2026) Astaxanthin on sperm freeze-thaw (MA). Sci Rep. PMID: 41714661.
40. Shokri-Mashhadi N et al. (2025) Carotenoid supplementation on glycemic control (MA). Eur J Clin Nutr. PMID: 39327454.
41. Zhong Y et al. (2025) Antioxidant supplementation in endometriosis (MA). Front Med. PMID: 41234925.
42. Arefpour H et al. (2024) Astaxanthin on liver enzyme levels. Int J Vitam Nutr Res. PMID: 38407143.

Key New Findings from 2025–2026 (from research agents)

43. ITP (2026) Astaxanthin did NOT extend lifespan in UM-HET3 mice — definitive negative for longevity. GeroScience. PMID: 41843349.
44. (2026) Astaxanthin suppresses thrombosis via dual platelet activation + coagulation inhibition. Br J Pharmacol. PMID: 41702374.
45. (2026) Sexually dimorphic improvement of aged muscle progenitor myogenicity. NPJ Aging. PMID: 41519810.
46. (2025) RCT: Improved oxidative markers, uric acid, symptoms in heart failure. PMID: 41162864.
47. (2025) RCT: AstaReal improved digital eye strain in children (first pediatric RCT). PMID: 40014233.
48. (2025) RCT: Adjunctive therapy reduced inflammation in community-acquired pneumonia. PMID: 40852606.
49. (2026) Inhibits tau aggregation via direct interaction with aggregation-prone segments. PMID: 41389844.
50. (2026) Alleviates ulcerative colitis via Nrf2-ferroptosis, independent of microbiota. PMID: 41338419.
51. (2026) ISSN position stand includes astaxanthin for sports antioxidant use. PMID: 41701327.
52. (2026) SR: Comprehensive systematic review of astaxanthin as antioxidant/anti-inflammatory in human health. PMID: 41596351.

New References from April 2026 Review

53. Maleki-Hajiagha A et al. (2026) Pilot RCT of astaxanthin in PCOS at OHSS risk, RAGE-NFκB pathway. Sci Rep. PMID: 41673418 — N=44, ↑oocyte maturity, ↓RAGE, ↓IL-6 in FF.
54. Aminullah Y et al. (2024) Astaxanthin ↑SOD ↓MDA in H&N cancer patients on cisplatin. Asian Pac J Cancer Prev. PMID: 39487992 — First human chemoprotection RCT.
55. Kurinnyi DA et al. (2025) Astaxanthin reduces chromosomal damage in glioblastoma patients during RT. Probl Radiac Med Radiobiol. PMID: 41469350 — Radioprotection.
56. Gonzalez DE et al. (2024) Astaxanthin on cardiometabolic health in firefighters RCT. J Int Soc Sports Nutr. PMID: 39568140.
57. Basereh A et al. (2025) Exercise + astaxanthin in T2DM: miRNA and Humanin mechanism. Sci Rep. PMID: 41249265.
58. Sharifi-Rigi A et al. (2025) Astaxanthin modulates T2DM inflammation via miRNAs, LPC, alpha-HB. Int J Endocrinol. PMID: 40881644.
59. Fereidouni F et al. (2024) Astaxanthin ↓cytokines, ↑ART outcomes in PCOS RCT. Inflammopharmacology. PMID: 38916710.
60. Jabarpour M et al. (2024) Astaxanthin on ER stress-apoptosis in PCOS PBMCs RCT. J Cell Mol Med. PMID: 39036884.
61. Tian D et al. (2026) Astaxanthin improves ART in poor ovarian responders via mitochondria. J Reprod Immunol. PMID: 41723936.
62. Khayyal MT et al. (2024) Comparative PK: standard vs micellar astaxanthin in humans. Eur J Drug Metab Pharmacokinet. PMID: 38748358.
63. Lao Y et al. (2026) CD36-mediated stereoisomeric selectivity of astaxanthin absorption. J Agric Food Chem. PMID: 41631482.
64. Ranjbari M et al. (2026) Anxiolytic and antidepressant effects of astaxanthin in rats. Front Pharmacol. PMID: 41929257 — First dedicated mood study.
65. Zhao L et al. (2024) Astaxanthin alleviates fibromyalgia pain + depression via NLRP3. Biomed Pharmacother. PMID: 38852510.
66. Lin YZ et al. (2025) Astaxanthin prevents glucocorticoid osteonecrosis via ferroptosis-JAK2/STAT3. J Agric Food Chem. PMID: 39903514.
67. Tao ZS et al. (2024) Astaxanthin prevents bone loss in osteoporotic rats. Redox Rep. PMID: 38623993.
68. Yousefi-Manesh H et al. (2025) Astaxanthin therapeutic effect on femoral fracture in rats. Tissue Cell. PMID: 40382952 — First fracture healing model.
69. Hong M et al. (2024) Astaxanthin attenuates diabetic kidney via podocyte autophagy. Ren Fail. PMID: 39011603.
70. Qian X, Wang Z (2025) Astaxanthin Nrf2/HO-1 attenuates indoxyl sulfate renal damage. Front Pharmacol. PMID: 41560720 — CKD model.
71. Ni S et al. (2025) Astaxanthin nanoprobiotic alleviates hyperuricemia via gut-kidney axis. Int J Biol Macromol. PMID: 41067355.
72. Albahadly WKY et al. (2026) Topical astaxanthin attenuates psoriasiform dermatitis via JAK-STAT. Molecules. PMID: 41976231 — First psoriasis model.
73. Madhavan A et al. (2026) Astaxanthin improves behavior + immunity in Shank3b autism model. Biomed Pharmacother. PMID: 41579706 — First autism study.
74. Tew TB, Yang CH (2026) Astaxanthin protects retinal Muller cells via SIRT1/AMPK/FOXO1. Exp Eye Res. PMID: 41581827.
75. Anto-Michel N et al. (2025) Astaxanthin limits atherosclerosis via inflammatory cell recruitment. PLoS One. PMID: 41171725.
76. Zhang J et al. (2025) Astaxanthin suppresses ferroptosis via Akt1-FoxO3a in ICH. J Pharmacol Sci. PMID: 41241442.
77. Liu S et al. (2026) Astaxanthin attenuates alcoholic liver injury via cGAS-STING. J Agric Food Chem. PMID: 41649288.
78. Moqaddam MA et al. (2024) Astaxanthin + CrossFit on adipo-myokines in obese males. Nutrients. PMID: 39275173.
79. Ayub Mohammed Salih S et al. (2024) Astaxanthin post-varicocelectomy semen quality triple-blind RCT. Food Sci Nutr. PMID: 39479675.
80. Rong C et al. (2026) Astaxanthin improves gut microbiota post-stroke. Sci Rep. PMID: 41559375 — Gut-brain axis.
81. Liu YF et al. (2024) Astaxanthin alleviates chronic prostatitis via Akkermansia. Phytomedicine. PMID: 38056144 — Gut-prostate axis.
82. Shalaby AM et al. (2026) Astaxanthin in cisplatin nephrotoxicity: ncRNA, ferroptosis. J Mol Histol. PMID: 41559443.
83. EFSA FEEDAP Panel (2026) Renewed authorization of astaxanthin as feed additive. EFSA J. PMID: 41972201 — Regulatory.
84. Martinez-Perez C et al. (2025) Nutritional supplementation for myopia prevention SR. Nutrients. PMID: 41515122.
85. Ghaiad HR et al. (2026) Diverse inflammopharmacological roles of astaxanthin. Review. PMID: 41507627.